Clinical Trial Update: Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant androgen deprivation therapy with abiraterone, with or without apalutamide, for high-risk prostate cancer (completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Apalutamide (apalutamide)

Snippet

Sponsor: Instituto do Cancer do Estado de São Paulo | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED